OraSure Technologies, Inc. (NASDAQ:OSUR) CEO Manner Carrie Eglinton Purchases 78,625 Shares

OraSure Technologies, Inc. (NASDAQ:OSUR) CEO Manner Carrie Eglinton bought 78,625 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The shares were bought at an average cost of $3.15 per share, for a total transaction of $247,668.75. Following the transaction, the chief executive officer now directly owns 1,259,664 shares of the company’s stock, valued at $3,967,941.60. This trade represents a 6.66 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

OraSure Technologies Trading Up 2.3 %

Shares of NASDAQ:OSUR opened at $3.13 on Friday. The firm has a market capitalization of $233.48 million, a PE ratio of 20.87 and a beta of 0.05. OraSure Technologies, Inc. has a 1-year low of $2.68 and a 1-year high of $8.04. The business’s 50 day moving average is $3.78 and its 200-day moving average is $4.01.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mackenzie Financial Corp raised its stake in shares of OraSure Technologies by 229.4% in the 4th quarter. Mackenzie Financial Corp now owns 134,051 shares of the medical instruments supplier’s stock valued at $484,000 after buying an additional 93,359 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in OraSure Technologies in the fourth quarter worth about $277,000. Two Sigma Advisers LP raised its position in OraSure Technologies by 36.9% in the fourth quarter. Two Sigma Advisers LP now owns 97,200 shares of the medical instruments supplier’s stock worth $351,000 after purchasing an additional 26,200 shares in the last quarter. Two Sigma Investments LP bought a new position in OraSure Technologies during the fourth quarter worth about $552,000. Finally, Systematic Financial Management LP boosted its holdings in OraSure Technologies by 33.7% during the fourth quarter. Systematic Financial Management LP now owns 1,673,609 shares of the medical instruments supplier’s stock valued at $6,042,000 after purchasing an additional 421,497 shares in the last quarter. 93.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Saturday, February 22nd.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.